Thermo Fisher Scientific (TMO)
(Real Time Quote from BATS)
$545.04 USD
+3.52 (0.65%)
Updated Apr 19, 2024 01:56 PM ET
3-Hold of 5 3
C Value C Growth C Momentum C VGM
Thermo Fisher Scientific (TMO) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$607.61 | $670.00 | $540.00 | 12.20% |
Price Target
Based on short-term price targets offered by 18 analysts, the average price target for Thermo Fisher Scientific comes to $607.61. The forecasts range from a low of $540.00 to a high of $670.00. The average price target represents an increase of 12.2% from the last closing price of $541.52.
Analyst Price Targets (18)
Broker Rating
Thermo Fisher Scientific currently has an average brokerage recommendation (ABR) of 1.63 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 20 brokerage firms. The current ABR compares to an ABR of 1.66 a month ago based on 19 recommendations.
Of the 20 recommendations deriving the current ABR, 12 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 60% and 15% of all recommendations. A month ago, Strong Buy made up 57.89%, while Buy represented 15.79%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 11 | 12 | 12 |
Buy | 3 | 3 | 3 | 3 | 3 |
Hold | 5 | 5 | 5 | 4 | 4 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.63 | 1.63 | 1.66 | 1.55 | 1.55 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/12/2024 | SVB Securities | Puneet Souda | Strong Buy | Strong Buy |
2/1/2024 | Raymond James | Andrew Cooper | Moderate Buy | Moderate Buy |
1/31/2024 | Evercore Partners | Vijay Kumar | Strong Buy | Strong Buy |
12/14/2023 | Robert W. Baird & Co. | Catherine W Schulte | Strong Buy | Strong Buy |
10/27/2023 | KeyBanc Capital Markets | Paul Knight | Hold | Hold |
10/25/2023 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.63 |
ABR (Last week) | 1.63 |
# of Recs in ABR | 20 |
Average Target Price | $607.61 |
LT Growth Rate | 11.10% |
Industry | Medical - Instruments |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | 4.70 |